Conversion to tacrolimus immunosuppression in renal transplant recipients: 12-month follow-up.
Citterio
F
F
Division of Organ Transplantation, Department of Surgery, Catholic University, Largo A. Gemelli 8, 00168 Rome, Italy.
Scatà
M C
MC
Romagnoli
J
J
Pozzetto
U
U
Nanni
G
G
Castagneto
M
M
D000328:Adult; D003404:Creatinine / Q000097:blood*; D016572:Cyclosporine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000188:drug therapy / Q000473:pathology; D006085:Graft Survival / Q000187:drug effects / Q000276:immunology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology / Q000502:physiology* / Q000523:psychology; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D011788:Quality of Life; D016559:Tacrolimus / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D016572:Cyclosporine; D003404:Creatinine; D009173:Mycophenolic Acid; D016559:Tacrolimus